241 related articles for article (PubMed ID: 25083816)
1. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.
Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB
Oncotarget; 2016 Sep; 7(37):58728-42. PubMed ID: 27623214
[TBL] [Abstract][Full Text] [Related]
4. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
5. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
[TBL] [Abstract][Full Text] [Related]
6. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.
Liem NL; Papa RA; Milross CG; Schmid MA; Tajbakhsh M; Choi S; Ramirez CD; Rice AM; Haber M; Norris MD; MacKenzie KL; Lock RB
Blood; 2004 May; 103(10):3905-14. PubMed ID: 14764536
[TBL] [Abstract][Full Text] [Related]
7. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
[TBL] [Abstract][Full Text] [Related]
8. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
10. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk CH; Smets LA; Van Wering ER; Van Der Does-Van Den Berg A
Blood; 1997 Oct; 90(7):2723-9. PubMed ID: 9326239
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
12. Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias--correlation to the expression of multidrug resistance proteins.
Fichtner I; Paal K; Borgmann A; Badiali L; Wurm R; Henze G
Anticancer Res; 2003; 23(3B):2657-64. PubMed ID: 12894554
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
[TBL] [Abstract][Full Text] [Related]
14. TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia.
Chu M; Yin K; Dong Y; Wang P; Xue Y; Zhou P; Wang Y; Wang Y
Oncotarget; 2017 Jan; 8(1):1405-1415. PubMed ID: 27902457
[TBL] [Abstract][Full Text] [Related]
15. Effects of chemotherapy agents used to treat pediatric acute lymphoblastic leukemia patients on bone parameters and longitudinal growth of juvenile mice.
Straszkowski L; Jovic T; Castillo-Tandazo W; Ritchie DS; Purton LE
Exp Hematol; 2020 Feb; 82():1-7. PubMed ID: 32006607
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor.
Bachmann PS; Gorman R; Mackenzie KL; Lutze-Mann L; Lock RB
Blood; 2005 Mar; 105(6):2519-26. PubMed ID: 15572593
[TBL] [Abstract][Full Text] [Related]
17. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers.
Toscan CE; Failes T; Arndt GM; Lock RB
J Biomol Screen; 2014 Dec; 19(10):1391-401. PubMed ID: 25104793
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
[TBL] [Abstract][Full Text] [Related]
20. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia.
Holleman A; den Boer ML; Kazemier KM; Janka-Schaub GE; Pieters R
Blood; 2003 Dec; 102(13):4541-6. PubMed ID: 12920041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
